Mitochondrial dysfunction and mitochondrion-targeted therapeutics in liver diseases

Area of Science:

• Hepatology
• Mitochondrial Biology
• Cellular Pathology

Background:

• The liver performs critical metabolic and detoxification functions, but is susceptible to damage.
• Liver injury often leads to defects in hepatocyte mitochondria, causing oxidative stress and metabolic issues.
• Disrupted mitochondrial quality control (MQC) exacerbates liver damage through inflammation and fibrosis.

Purpose of the Study:

• To review the link between mitochondrial disorders and liver disease pathophysiology.
• To explore mitochondrion-targeting therapeutics for hepatic disorders.
• To focus on recent advances in MQC and mitochondrial-derived damage-associated molecular patterns (DAMPs) in liver disease.

Main Methods:

• Literature review of studies on mitochondrial dysfunction in liver injury.
• Analysis of research on MQC mechanisms in hepatic diseases.
• Examination of studies investigating DAMPs in liver pathology and treatment.

Main Results:

• Mitochondrial defects are central to liver injury, initiating apoptosis and inflammation.
• Impaired MQC exacerbates liver damage and disease progression.
• Restoring mitochondrial homeostasis through MQC improvement benefits liver health.

Conclusions:

• Mitochondrial dysfunction is a key driver of liver disease.
• Targeting mitochondria and enhancing MQC represent promising therapeutic strategies for liver disorders.
• Understanding DAMPs is crucial for developing novel liver disease treatments.